✓ Translated by DotMD AI Clinical Council Source: Clinical breast cancer • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #42431149 ↗

Phase III Randomized Trial: Minimal Clinically Important Differences to Determine Meaningful Change in the Skin Symptom Assessment (SSA) Questionnaire for the Randomized Controlled Trial of Mepitel Film Versus Standard of Care for the Prevention of Acute and Chronic Dermatitis in Breast Cancer Radiation Treatment (N = 376)

Original Paper Title: “Minimal Clinically Important Differences to Determine Meaningful Change in the Skin Symptom Assessment (SSA) Questionnaire for the Randomized Controlled Trial of Mepitel Film Versus Standard of Care for the Prevention of Acute and Chronic Dermatitis in Breast Cancer Radiation Treatment”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 376
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Determining MCIDs can help HCPs determine when treatments meaningfully improve patient QoL. MCIDs may also guide decisions to introduce alternative or additional treatments.
  • Study Design & Sample: Phase III Randomized Trial published in Clinical breast cancer (N = 376 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Clinical breast cancer (2026), this phase iii randomized trial evaluating 376 human participants investigated: Changes in patient-reported outcomes may be statistically significant, but not necessarily clinically significant. Key clinical takeaway: Determining MCIDs can help HCPs determine when treatments meaningfully improve patient QoL. MCIDs may also guide decisions to introduce alternative or additional treatments.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Clinical breast cancer, 2026-08-15; N = 376; Rigor 87/100): Determining MCIDs can help HCPs determine when treatments meaningfully improve patient QoL. MCIDs may also guide decisions to introduce alternative or additional treatments.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: quality-choice-effervescent-cold-relief-plus-aspirin-chlorpheniramine → Rx: quality-choice-pain-relief-powder-aspirin-and-caffeine → Condition: callus → Condition: scar-keloid →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42431149: Phase III Randomized Trial: Minimal Clinically Important Differences to Determine Meaningful Change in the Skin Symptom Assessment (SSA) Questionnaire for the Randomized Controlled Trial of Mepitel Film Versus Standard of Care for the Prevention of Acute and Chronic Dermatitis in Breast Cancer Radiation Treatment (N = 376)

3 of 3 Free Questions Remaining